FDG PET/CT is a vital imaging tool in the management of gynecological cancer, particularly in ovarian, cervical, and endometrial cancer for accurate staging before treatment, detection of recurrence, and evaluation of therapeutic response.
The use of FDG PET/CT examination has high clinical impact, capable of significantly modifying treatment plans for patients with gynecological cancer by providing more accurate staging and monitoring information, improving patient outcomes, and assisting in radiotherapy planning by precisely defining the metabolically active tumor volume.
Main Indications for 18FDG PET/CT Examination
• Staging and restaging of vulvar, cervical, and endometrial cancer in patients who are candidates for radical treatment (especially in cervical cancer, other imaging methods should have been performed first).
• Monitoring response to chemo/radiotherapy in locally advanced cervical cancer.
• Suspected recurrence of vulvar, cervical, and endometrial cancer when the results of other imaging studies are equivocal.
• Detection of ovarian cancer recurrence in patients with elevated CA-125 levels and negative/equivocal results from other imaging studies.